Latest Breaking News On - Drug development of gustave roussy cancer center - Page 1 : comparemela.com

SOTIO Biotech: SOTIO Doses First Patient in AURELIO-04 Phase 2 Trial of SOT101 in Combination with KEYTRUDA (pembrolizumab)

AURELIO-04 will enroll up to 320 patients and test the combination in multiple solid tumor indicationsClinical collaborator, MSD (Merck & Co., Inc., Rahway, NJ, USA), will supply KEYTRUDA for the study

United statesCzech republicKostenloser wertpapierhandelRichard sachseMichael tattoryPeter grellRichard kapsaMerck co incLifesci communicationsMerck sharp dohmeMasaryk memorial cancer instituteDrug development of gustave roussy cancer centerSuperagonist technologyChief medical officerManaging directorInpatient unit

Investegate |SOTIO Biotech Announcements | SOTIO Biotech: SOTIO Doses First Patient in AURELIO-04 Phase 2 Trial of SOT101 in Combination with KEYTRUDA® (pembrolizumab)

Investegate announcements from SOTIO Biotech, SOTIO Doses First Patient in AURELIO-04 Phase 2 Trial of SOT101 in Combination with KEYTRUDA® (pembrolizumab)

Czech republicUnited statesRichard sachseMichael tattoryPeter grellRichard kapsaMerck co incMerck sharp dohmeLifesci communicationsMasaryk memorial cancer instituteDrug development of gustave roussy cancer centerSuperagonist technologyFirst patientChief medical officerManaging directorInpatient unit

SOTIO Doses First Patient in AURELIO-04 Phase 2 Trial of SOT101 in Combination with KEYTRUDA® (pembrolizumab)

SOTIO Doses First Patient in AURELIO-04 Phase 2 Trial of SOT101 in Combination with KEYTRUDA® (pembrolizumab)
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.

Czech republicUnited statesRichard sachsePeter grellMerck co incMerck sharp dohmeMasaryk memorial cancer instituteDrug development of gustave roussy cancer centerSuperagonist technologyChief medical officerManaging directorInpatient unitDrug developmentGustave roussy cancer centerMerck sharp

SOTIO Biotech: Interim Data from the Phase 1/1b AURELIO-03 Trial of SOT101 Presented at the AACR 2022 Annual Meeting

PRAGUE, Czech Republic and BASEL, Switzerland and CAMBRIDGE, Mass, April 12, 2022 (GLOBE NEWSWIRE) Interim Results of the Phase 1 AURELIO-03 study of SOT101 in combination with pembrolizumab for

Czech republicUnited kingdomUnited statesKostenloser wertpapierhandelStephane champiatMichael tattoryRadek spisekRichard kapsaAmerican association for cancer researchLifesci communicationsGustave roussy cancer centerDrug development of gustave roussy cancer centerAmerican associationCancer researchAnnual meetingInpatient unit

Investegate |SOTIO Biotech Announcements | SOTIO Biotech: Interim Data from the Phase 1/1b AURELIO-03 Trial of SOT101 Presented at the AACR 2022 Annual Meeting

Investegate announcements from SOTIO Biotech, Interim Data from the Phase 1/1b AURELIO-03 Trial of SOT101 Presented at the AACR 2022 Annual Meeting

Czech republicUnited kingdomUnited statesStephane champiatMichael tattoryRadek spisekRichard kapsaAmerican association for cancer researchLifesci communicationsGustave roussy cancer centerDrug development of gustave roussy cancer centerInterim dataAmerican associationCancer researchAnnual meetingInpatient unit